SCHEMBL4454297

SCHEMBL4454297

NCCOCCOCCOCCOC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 4/20 0.78
DUT P33316 1/20 0.48
TK2 O00142 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.41
TAAR1 Q96RJ0 2/20 0.41
HRH4 Q9H3N8 1/20 0.40
KDM4E B2RXH2 2/20 0.37
ALOX15 P16050 2/20 0.37
TSHR P16473 2/20 0.37
MEN1 O00255 1/20 0.37
TRPM2 O94759 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
THRB P10828 1/20 0.37
HPGD P15428 1/20 0.37
ALOX12 P18054 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11913616 1.00 KIF11 (0.78) KIF11DUTTK2SMN1; SMN2TAAR1
SCHEMBL28661706 1.00 KIF11 (0.78) KIF11DUTTK2SMN1; SMN2TAAR1
SCHEMBL13671082 1.00 KIF11 (0.78) KIF11DUTTK2SMN1; SMN2TAAR1
SCHEMBL26176912 0.90 KIF11 (0.65) KIF11DUTTK2HRH4ALOX15
SCHEMBL26176885 0.90 KIF11 (0.65) KIF11DUTTK2HRH4ALOX15
SCHEMBL26176886 0.90 KIF11 (0.65) KIF11DUTTK2HRH4ALOX15
SCHEMBL26176905 0.90 KIF11 (0.65) KIF11DUTTK2HRH4ALOX15
SCHEMBL31430932 0.90 KIF11 (0.65) KIF11DUTTK2HRH4ALOX15
SCHEMBL26176899 0.90 KIF11 (0.65) KIF11DUTTK2HRH4ALOX15
SCHEMBL26176887 0.90 KIF11 (0.65) KIF11DUTTK2HRH4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598421-B2 Materials for the delivery of biologically-active material to cells UCL BIOMEDICA PLC (GB) 2009-10-06 US disclosed
US-7598421-B2 Materials for the delivery of biologically-active material to cells UCL BIOMEDICA PLC (GB) 2009-10-06 US disclosed
US-7598421-B2 Materials for the delivery of biologically-active material to cells UCL BIOMEDICA PLC (GB) 2009-10-06 US disclosed
WO-2005117985-A2 LIPOPOLYPLEX CONSTRUCT WITH AN INTEGRIN BINDING PEPTIDE FOR DELIVERY OF NUCLEIC ACIDS, PEPTIDES OR DRUGS UCL BIOMEDICA PLC (GB) 2005-12-15 WO disclosed
US-20050245446-A1 Materials for the delivery of biologically-active material to cells NANOGENICS LIMITED (GB) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245446-A1 Materials for the delivery of biologically-active material to cells ITGB1, ITGA2B, ITGB2 KIF11 2529/4885DUT 1642/4885TK2 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.